Pluri (PLUR) Stock Price, News & Analysis

Company Overview

Pluri Inc. is a clinical-stage biotechnology company dedicated to the development, manufacturing and commercialization of off-the-shelf cell therapy products based on proprietary placental-expanded (PLX) cell lines. Leveraging a three-dimensional cell expansion platform, the company generates PLX cells—mesenchymal-like cells derived from full-term placenta—which exhibit immunomodulatory, pro-angiogenic and anti-inflammatory properties. Pluri’s pipeline includes PLX-PAD for the treatment of critical limb ischemia, muscle regeneration and orthopedic conditions; PLX-R18 targeting hematopoietic recovery following radiation exposure; and PLX-COVID-19 for acute respiratory distress syndrome associated with viral infections.

Headquartered in Haifa, Israel, with additional operations in the United States, Pluri operates a fully integrated, cGMP-compliant manufacturing facility capable of producing large-scale cell therapy batches in bioreactors of up to 60,000 liters. This scalable infrastructure underpins the company’s strategy to advance multiple clinical programs in parallel, including ongoing Phase II and Phase III studies across North America and Europe. Pluri has established strategic collaborations with governmental agencies, research institutions and industry partners to support accelerated development through regulatory pathways such as the U.S. FDA’s regenerative medicine advanced therapy (RMAT) designation.

Founded in 2001, the company completed its initial public offering on the Nasdaq under the ticker PLUR in early 2024 following the merger of Pluristem Therapeutics and Pluri Biotechnology. Under the leadership of Chief Executive Officer Tal Vaks, Pluri is focused on translating its platform technology into safe, scalable therapies addressing unmet medical needs in cardiovascular, hematological and respiratory indications. With a multicultural team of scientists and industry veterans, Pluri aims to deliver affordable, off-the-shelf cell therapies that can be shipped directly to treatment centers worldwide.

Key Stats

• Today's Range: $4.84 to $5.31
• 50-Day Range: $3.96 to $5.83
• 52-Week Range: $3.33 to $7.13
• Volume: 13,104 shs
• Average Volume: 20,482 shs
• Market Capitalization: $38.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Pluri Stock Analysis - MarketRank™

Pluri scored higher than 69% of companies evaluated by MarketBeat, and ranked 328th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pluri has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pluri has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pluri is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pluri is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pluri has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.70% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pluri does not currently pay a dividend.

Dividend Growth

Pluri does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.70% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 12.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.93

News Sentiment

Pluri has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pluri this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for PLUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Pluri to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Pluri insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,500,001.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

25.93% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.59% of the stock of Pluri is held by institutions.

PLUR Stock Analysis - Frequently Asked Questions

How have PLUR shares performed this year?

Pluri's stock was trading at $4.28 on January 1st, 2025. Since then, PLUR shares have increased by 15.5% and is now trading at $4.9450.

How were Pluri's earnings last quarter?

Pluri Inc. (NASDAQ:PLUR) released its earnings results on Tuesday, May, 13th. The company reported ($0.94) earnings per share for the quarter. The company earned $0.43 million during the quarter. Pluri had a negative trailing twelve-month return on equity of 4,191.91% and a negative net margin of 2,563.29%.

When did Pluri's stock split?

Pluri's stock reverse split on the morning of Monday, April 1st 2024.The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Pluri?

Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pluri own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pluri investors own include Digital Turbine (APPS), Lightning eMotors (ZEV), Archer Aviation (ACHR), ChargePoint (CHPT) and Canoo (GOEV).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 9/16/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PLUR
• CIK: 1158780
• Web: pluri-biotech.com
• Phone: 972747108600
• Fax: 972-74-710-8787
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pluri: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +142.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.89 million
• Net Margins: -2,563.29%
• Pretax Margin: -1,789.02%
• Return on Equity: -4,191.91%
• Return on Assets: -85.40%

Debt

• Debt-to-Equity Ratio: 51.65
• Current Ratio: 4.81
• Quick Ratio: 4.81

Sales & Book Value

• Annual Sales: $1.03 million
• Price / Sales: 37.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 4.95

Miscellaneous

• Outstanding Shares: 7,833,000
• Free Float: 5,802,000
• Market Cap: $38.73 million
• Optionable: Optionable
• Beta: 0.79